ESC 365 - What is the evidence for empagliflozin in HF?

Open Access

What is the evidence for empagliflozin in HF?

Session: A new era for HFpEF – Exploring the role of empagliflozin in practice

Topic: Chronic Heart Failure

Speaker: Professor J. Butler (Dallas, US)

Sponsored by Boehringer Ingelheim and Eli Lilly and Company

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

116 presentations

18 followers

3 more presentations in this session

Welcome and introduction.

Speaker: Professor A. Stewart Coats (Sydney, AU)

Using empagliflozin for HFpEF treatment - what does this look like in practice?

Speaker: Doctor S. Zieroth (Winnipeg, CA)

Panel discussion and close.

Speaker: Professor A. Stewart Coats (Sydney, AU)

Access the full session

A new era for HFpEF – Exploring the role of empagliflozin in practice

Speakers: Professor J. Butler, Professor A. Stewart Coats, Doctor S. Zieroth, Professor A. Stewart Coats

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources